[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352315-105":59,"doc-detail-352315-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","sumoylation-machinery-protein-pias4-role-in-breast-cancer-cell-proliferation-and-drug-sensitivity","SUMOylation machinery protein, PIAS4 role in breast cancer cell proliferation and drug sensitivity","","Breast cancer treatment is hindered by resistance to doxorubicin (DOX), a challenge linked to post-translational SUMOylation. PIAS4, a SUMO E3 ligase, regulates genome stability and stress responses, yet its role in breast cancer progression and DOX resistance is unclear. This study evaluates SUMOylation machinery gene expression in naked mole-rat tissues versus MCF-7 cells and tests PIAS4 overexpression effects on proliferation, invasion, drug sensitivity, and related protein changes under DOX exposure.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sumoylation-machinery-protein-pias4-role-in-breast-cancer-cell-proliferation-and-drug-sensitivity/352315/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sumoylation-machinery-protein-pias4-role-in-breast-cancer-cell-proliferation-and-drug-sensitivity/352315.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this study on PIAS4?","Question",{"text":113,"@type":114},"To investigate whether PIAS4 mediates doxorubicin (DOX) resistance and contributes to breast cancer progression through SUMOylation-related mechanisms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were SUMOylation machinery genes assessed?",{"text":118,"@type":114},"SUMOylation pathway mRNA expression profiles were compared between naked mole-rat intestinal tissues and human breast cancer cell lines, including qPCR measurements.",{"name":120,"@type":111,"acceptedAnswer":121},"What effect does PIAS4 overexpression have in MCF-7 cells under DOX treatment?",{"text":122,"@type":114},"PIAS4 overexpression decreases colony formation and invasiveness and reduces resistance to DOX, with Western blot results showing downregulation of Bcl-2 after DOX treatment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352315,1790158948,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Molecular Biology Reports (2026) 53:336  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1033-025-11423-0  \nORIGINAL ARTICLE  \nSUMOylation machinery protein, PIAS4 role in breast cancer cell proliferation and drug sensitivity  \nMohammed A. M. Salih1,2,4 · Mohamed M. A. E. L. Salem3 · Muhammad Ali Shahid1 · Hussein A. S. Elrewey1,5 · Ritchie Williamson2 · Sriharsha Kantamneni1,2  \nReceived: 27 August 2025 / Accepted: 29 December 2025 © The Author(s) 2025  \nAbstract  \nPurpose Breast cancer is a significant global health issue, with resistance to doxorubicin (DOX) posing a major challenge to effective treatment. SUMOylation, a post-translational modification process, is linked to cancer progression and therapy resistance. PIAS4, a SUMO E3 ligase involved in maintaining genome stability and stress response, may play a role in these mechanisms. However, its function in breast cancer progression and DOX resistance remains uncertain. This study investigates the potential role of PIAS4 in mediating DOX resistance in breast cancer.  \nMethods and results Naked mole-rats (NMRs) are cancer-resistant rodents with improved genome maintenance, yet the role of SUMOylation in this trait remains unclear. SUMOylation machinery gene expression levels are investigated using qPCRin NMR tissue in comparison with carcinogenic breast cancer (MCF-7) cell line. Functional studies are performed in MCF-7 cells overexpressing PIAS4 to demonstrate effects on proliferation, invasion, drug sensitivity, and protein expression in the presence and absence of DOX treatment. While most SUMOylation genes were expressed at low levels in NMR intestinal tissues, PIAS4 showed higher expression compared to MCF-7 cells. PIAS4 overexpression in MCF-7 cells significantly decreases colony formation, invasiveness, and resistance to DOX. Western blot analysis showed downregulated Bcl-2 protein levels after DOX treatment, indicating a potential role in apoptosis evasion.  \nConclusion PIAS4 expression level plays a role in breast cancer cell survival, invasiveness, and chemoresistance, partly by altering anti-apoptotic pathways. These findings position PIAS4 as a potential biomarker and therapeutic target for overcoming resistance to anthracycline-based therapies in breast cancer.  \nKeywords Breast cancer · MCF-7 · Naked mole-rat · PIAS4 · SUMOylation  \n􀀍 Sriharsha Kantamneni[s.kantamneni@bradford.ac.uk](s.kantamneni@bradford.ac.uk)  \n1 Institute of Cancer Therapeutics, University of Bradford, Bradford, UK  \n2 School of Pharmacy, Optometry and Medical Sciences, Faculty of Health and Social Care, University of Bradford, Bradford, UK  \n3 University of Bradford International College, University of Bradford, Bradford, UK  \n4 Present address: Department of Health and Social Care, Scholars School System, Leeds Trinity University, Leeds, UK  \n5 Faculty of Pharmacy, Tobruk University, Tobruk, Libya  \nIntroduction  \nEvery year, just over 2.3 million new breast cancer (BC) cases are diagnosed in women [1] . Early detection and treatments, such as anthracyclines (e.g., doxorubicin), have increased survival rates, although treatment resistance and cancer recurrence remain significant challenges [2] . Doxorubicin (DOX) works by intercalating with DNA, inhibiting topoisomerase II, and generating reactive oxygen species (ROS) to induce cell death [3] . However, cancer cells can develop resistance to DOX through increased drug efflux, changes in topoisomerase II (reliance on beta-isoform), and modulation of cell survival pathways [4] . Previous studies indicate that SUMOylation plays a role in these adaptive responses. PIAS4, a component of this process, helps oncoproteins persist longer and facilitates DNA double-strand break repair [5, 6] .  \n1 3  \nE3 SUMO (Small Ubiquitin-like Modifier) ligases belong to the Protein Inhibitor of Activated STAT (PIAS) family. These ligases have an influence on post-translational modification, mainly SUMOylation and change protein stability, subcell","cbCaiuf4PfaRNCPv","https://ap.wps.com/l/cbCaiuf4PfaRNCPv","pdf",1489469,"English","# Abstract\n# Introduction\n## Breast cancer burden and DOX resistance\n## PIAS4 and SUMOylation background\n## Naked mole-rat as a model\n# Methods and results\n## Gene expression comparison\n## PIAS4 overexpression in MCF-7 cells\n## DOX response and protein changes\n# Conclusion","[{\"question\":\"What is the main purpose of this study on PIAS4?\",\"answer\":\"To investigate whether PIAS4 mediates doxorubicin (DOX) resistance and contributes to breast cancer progression through SUMOylation-related mechanisms.\"},{\"question\":\"How were SUMOylation machinery genes assessed?\",\"answer\":\"SUMOylation pathway mRNA expression profiles were compared between naked mole-rat intestinal tissues and human breast cancer cell lines, including qPCR measurements.\"},{\"question\":\"What effect does PIAS4 overexpression have in MCF-7 cells under DOX treatment?\",\"answer\":\"PIAS4 overexpression decreases colony formation and invasiveness and reduces resistance to DOX, with Western blot results showing downregulation of Bcl-2 after DOX treatment.\"}]","SUMOylation machinery protein, PIAS4 role in breast cancer cell proliferation and drug sensitivity | PDF",1790098888,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66c36a5dcf1f6f7c9688714a105a813c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/708fe81864e12b9642ae085609d7a72d.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd41250a27e41e62137200dc61b9d2b9.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/261212e3523ae1d1eb9f15516f8424d8.webp",980,1301]